Israel's MediWound targets $80m IPO
This article was originally published in Clinica
Israeli wound care specialist MediWound hopes to raise up to $80m in an initial public offering, selling 5 million shares at $14-16 each. The Yavne-based company plans to list on the NASDAQ under the symbol MDWD. Founded in 2001, MediWound is developing products for the management of severe burns and chronic wounds. Its flagship product, NexoBrid, for the removal of burn wound eschar (dead tissue) is approved in Europe for adults with deep partial- and full-thickness thermal burns – MediWound says it is ready to launch there. Fellow Israeli firm Teva Pharmaceutical Industries is an investor in MediWound.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.